Using this concept, albeit in a different context, genetically engineered, anti-tumor T cell products with integrated artificial receptors engaging transforming growth factor β (TGF-β), an inhibitor of effector T and NK cells and tumor antigen-specific cellular immunity, were capable of overcoming the TGF-β-induced tumor immune evasion, being shielded from the inhibitory effects of TGF-β or functionally empowered via the conversion of TGF-β suppressive signal to an activating signal [164,165,166,167]. The gene discussed is TGFB1; the disease is neoplasm.